AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg Oral Tablet
Description: 2 × 200 mg tablets at Hours 0, 8, and 16
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of PR tablet
Description: 2 tablets up to four times in 24 hours
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of PR tablet
Description: 2 tablets up to four times in 24 hours
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of PR tablet
Description: 2 tablets up to four times in 24 hours
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of IR tablet
Description: 2 tablets up to four times in 24 hours
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of IR tablet
Description: 2 tablets up to four times in 24 hours
Study NCT03785756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of IR tablet
Description: 2 tablets up to four times in 24 hours
Study NCT03749811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
Study NCT00193180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib
Study NCT00193180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study NCT01517464 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-94
Description: SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
Study NCT01358058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation
Description: Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
Study NCT01506999 — intervention group
Intervention type: BIOLOGICAL
Intervention: MULTIGENE SCREENING FOR SINGLE SNPS
Description: DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
Study NCT02183779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cooling box
Study NCT02183779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA and Fluconazole dermic injection
Study NCT02691325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
Study NCT02691325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose.
Study NCT04150094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Description: Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
Study NCT04150094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training + intravaginal vibratory stimulus
Description: Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
Study NCT00356343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES Strength Training
Description: Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
Study NCT00356343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volitional Strength Training
Description: Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
Study NCT02014168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viroflu® and MVA-NP+M1
Description: 2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu.
Study NCT02014168 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viroflu® and saline placebo
Description: 2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo.
Study NCT02691325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
Study NCT04172935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Presbyopic Glasses/ Intervention Group
Description: Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
Study NCT02325492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Study NCT02325492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03694834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics.
Study NCT02407288 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial dirrect current stimulation
Description: The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
Study NCT03694834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: Hysterectomy/Surgical Staging per institutional standard of care.
Study NCT02407288 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Study NCT02325492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02325492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT02325492 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound
Study NCT02491645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory interventions
Description: 1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done.
Study NCT02192645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfujiu
Study NCT03308799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 cream
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
Study NCT03308799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cal/BDP combination
Description: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
Study NCT03308799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: Vehicle Cream
Study NCT00969111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
Description: Postop High Risk
Study NCT00969111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton (prostate bed) to 70.2 CGE
Description: Salvage Non-High Risk
Study NCT00969111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
Description: Salvage High Risk
Study NCT00969111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton to 66.6 CGE
Description: Post-Op Non High Risk
Study NCT03473184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein 1% ointment
Description: Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
Study NCT03517501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART-123
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study NCT02688985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered as IV infusion.
Study NCT03517501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - Placebo
Description: Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
Study NCT02688985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
Study NCT02688985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyloprednisolone
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
Study NCT02577237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person education sessions
Description: The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
Study NCT02577237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Booklet
Description: Radiation Oncology Nurse will hand participant the NCI booklet
Study NCT02577237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
Study NCT02577237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
Study NCT02577237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
Study NCT02577237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
Study NCT00066066 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
Study NCT00066066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
Study NCT00066066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
Study NCT00066066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
Study NCT02268409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection
Study NCT02245542 — intervention group
Intervention type: DRUG
Intervention: ALNA®OCAS®
Study NCT02805335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KTFIX PLUS
Study NCT04538066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryostatin 1
Description: Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
Study NCT04538066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
Study NCT02155738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Study NCT02155738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV normal saline
Study NCT03324763 — intervention group
Intervention type: OTHER
Intervention: stool sampling
Description: A stool sample will be collected to perform the H. pylori antigen test
Study NCT01918527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Orally on days 1-14: 2000 mg/m2/day q3w
Study NCT01918527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Intravenously on day 1: 130 mg/m2 q3w
Study NCT04122859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip Skin Closure Device
Description: The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
Study NCT00542919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily until progressive disease
Study NCT04428892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedagogyc Strategy
Description: Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
Study NCT04428892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedagogyc Strategy
Description: Simulation can be used as a pedagogic tool that provides students with significant learning regarding decision-making in interacting with people, in this case patients with LBP. It is a potential strategy for developing diverse skills focused on the safety of the patient and the therapist.
Study NCT02688985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
Study NCT00706641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
Study NCT00706641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
Study NCT02192645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
Study NCT01996514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose with water
Description: Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
Study NCT01996514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-caloric sweetener with water
Description: 0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
Study NCT04541043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefecon 16mg daily
Description: All study patients received Nefecon 16 mg daily for 9 months.
Study NCT02927990 — intervention group
Intervention type: OTHER
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention according to standard of care
Study NCT03031613 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP group
Description: Application of 5cmH20 positive end expiratory pressure
Study NCT03031613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP group
Description: No application of positive end expiratory pressure
Study NCT02373176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PRC 4016 (Icosabutate)
Description: Single oral dose
Study NCT00026559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock Device
Description: Shock Device
Study NCT00026559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Startle Device
Description: Auditory Startle Device
Study NCT02546193 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
Study NCT02546193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.